These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7691114)

  • 1. Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients.
    Maiche AG; Muhonen T
    Eur J Cancer; 1993; 29A(10):1403-5. PubMed ID: 7691114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer.
    Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
    Oncol Rep; 2001; 8(4):861-6. PubMed ID: 11410799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide.
    Koumakis G; Vassilomanolakis M; Barbounis V; Hatzichristou E; Demiri S; Plataniotis G; Pamouktsoglou F; Efremidis AP
    Oncology; 1999; 56(1):28-35. PubMed ID: 9885374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.
    Schröder CP; de Vries EG; Mulder NH; Willemse PH; Sleijfer DT; Hospers GA; van der Graaf WT
    J Antimicrob Chemother; 1999 May; 43(5):741-3. PubMed ID: 10382902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia.
    Lalami Y; Paesmans M; Aoun M; Munoz-Bermeo R; Reuss K; Cherifi S; Alexopoulos CG; Klastersky J
    Support Care Cancer; 2004 Oct; 12(10):725-30. PubMed ID: 15235901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
    Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
    Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
    Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte colony-stimulating factor for gastrointestinal perforation in patients with leukopenia.
    Nishida T; Hasegawa J; Nakao K; Fujita N
    J Trauma; 1996 May; 40(5):727-32. PubMed ID: 8614070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of sulfamethoxazole/trimethoprim plus norfloxacin versus sulfamethoxazole/trimethoprim alone for the prophylaxis of bacteria infection during chemotherapy for lung cancer.
    Nagatomo A; Watanabe K; Kunikane H; Okamoto H; Kunitoh H
    Lung Cancer; 1998 Feb; 19(2):121-5. PubMed ID: 9567248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two strategies for the treatment of radiogenic leukopenia using granulocyte colony stimulating factor.
    Adamietz IA; Rosskopf B; Dapper FD; von Lieven H; Boettcher HD
    Int J Radiat Oncol Biol Phys; 1996 Apr; 35(1):61-7. PubMed ID: 8641928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
    de Wit R; Verweij J; Bontenbal M; Kruit WH; Seynaeve C; Schmitz PI; Stoter G
    J Natl Cancer Inst; 1996 Oct; 88(19):1393-8. PubMed ID: 8827017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
    Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
    Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy.
    Sulpher J; Giguere P; Hopkins S; Dent S
    Support Care Cancer; 2016 Jul; 24(7):3185-9. PubMed ID: 26939922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
    Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
    J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsiveness to G-CSF before leukopenia predicts defense to infection in high-dose chemotherapy recipients.
    Straka C; Oduncu F; Hinke A; Einsele H; Drexler E; Schnabel B; Arseniev L; Walther J; König A; Emmerich B
    Blood; 2004 Oct; 104(7):1989-94. PubMed ID: 15205265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
    Miles DW; Fogarty O; Ash CM; Rudd RM; Trask CW; Spiro SG; Gregory WM; Ledermann JA; Souhami RL; Harper PG
    J Clin Oncol; 1994 Jan; 12(1):77-82. PubMed ID: 7505809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.